(Q43812139)

27 November 2017

title

Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells (English)

1 reference

27 November 2017

1 reference

6

März W

1 reference

27 November 2017

Scharnagl H

1

1 reference

27 November 2017

Schinker R

2

1 reference

27 November 2017

Gierens H

3

1 reference

27 November 2017

Nauck M

4

1 reference

27 November 2017

Wieland H

5

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 December 2001

1 reference

27 November 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

Biochemical Pharmacology

1 reference

27 November 2017

volume

62

1 reference

27 November 2017

issue

11

1 reference

27 November 2017

page(s)

1545-1555

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

A receptor-mediated pathway for cholesterol homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Regulation of the mevalonate pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Two tandem binding sites for sterol regulatory element binding proteins are required for sterol regulation of fatty-acid synthase promoter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Polyunsaturated fatty acids decrease expression of promoters with sterol regulatory elements by decreasing levels of mature sterol regulatory element-binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Sterol regulation of fatty acid synthase promoter. Coordinate feedback regulation of two major lipid pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Defective utilization of cholesterol esters from low-density lipoprotein in a human acute lymphoblastic leukemia T cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

19 Receptor-mediated endocytosis of low-density lipoprotein in cultured cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Human fatty-acid synthase gene. Evidence for the presence of two promoters and their functional interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Interleukin-6 stimulates LDL receptor gene expression via activation of sterol-responsive and Sp1 binding elements.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Comparison of statins in hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Discovery, biochemistry and biology of lovastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Effect of lovastatin on the secretion of very low density lipoprotein lipids and apolipoprotein B in the hypertriglyceridemic Zucker obese rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Effects of colestipol alone and in combination with simvastatin on apolipoprotein B metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

In HepG2 cells, translocation, not degradation, determines the fate of the de novo synthesized apolipoprotein B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Sterol regulatory element-binding protein negatively regulates microsomal triglyceride transfer protein gene transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

The effects of simvastatin and cholestyramine, alone and in combination, on hepatic cholesterol metabolism in the male rat. off

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

Synthesis and secretion of apolipoprotein B from cultured liver cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2801%2900790-0

10.1016/S0006-2952(01)00790-0

7 January 2021

Identifiers

DOI

1 reference

27 November 2017

1 reference